Is HIV-1 evolving to a less virulent form in humans?

Nature Reviews Microbiology

Volumn 5, Issue 2, 2007, Pages 141-151

  Ariën, Kevin K ^a,b   Vanham, Guido ^a   Arts, Eric J ^c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE COURSE; EPIDEMIC; GENE MUTATION; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR PHYLOGENY; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SEXUAL TRANSMISSION; STRAIN DIFFERENCE; VERTICAL TRANSMISSION; VIRION; VIRUS ATTENUATION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS TYPING; VIRUS VIRULENCE;

ANIMALS; DISEASE OUTBREAKS; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV-1; HUMANS; PHYLOGENY; VIRAL LOAD; VIRULENCE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33846502673     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1594     Document Type: Article

References (165)

1. Lemey, P., Pybus, O. G., Van, D. S. & Vandamme, A. M. A Bayesian statistical analysis of human T-cell lymphotropic virus evolutionary rates. Infect. Genet. Evol. 5, 291-298 (2005).
2. Van, D. S., Salemi, M. & Vandamme, A. M. Dating the origin of the African human T-cell lymphotropic virus type-i (HTLV-I) subtypes. Mol. Biol. Evol. 18, 661-671 (2001).
3. Yoshida, M. Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene 24, 5931-5937 (2005).
4. Coulthart, M. B., Posada, D., Crandall, K. A. & Dekaban, G. A. On the phylogenetic placement of human T cell leukemia virus type 1 sequences associated with an Andean mummy. Infect. Genet. Evol. 6, 91-96 (2006).
5. Korber, B. et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789-1796 (2000).
6. UNAIDS/WHO. AIDS Epidemic Update 2006. [online], http://www.unaids,org/ HIV_data/epi2006/ (UNAIDS/WHO, Geneva, 2006).
7. Geisbert, T. W. & Jahrling, P. B. Exotic emerging viral diseases: progress and challenges. Nature Med. 10, S110-S121 (2004).
8. Doherty, P. C., Turner, S. J., Webby, R. G. & Thomas, P. G. Influenza and the challenge for immunology. Nature Immunol. 7, 449-455 (2006).
9. Perlman, S. & Dandekar, A. A. Immunopathogenesis of coronavirus infections: Implications for SARS. Nature Rev. Immunol. 5, 917-927 (2005).
10. Gage, K. L. & Kosoy, M. Y. Natural history of plague: Perspectives from more than a century of research. Annu. Rev. Entomol. 50, 505-528 (2005).
11. Drancourt, M., Houhamdi, L. & Raoult, D. Yersinia pestis as a telluric, human ectoparasite-borne organism. Lancet Infect. Dis. 6, 234-241 (2006).
12. Fenner, F. & Radcliffe, F. N. Myxomatosis (Cambridge University Press, Cambridge, 1965).
13. Zuniga, M. C. A pox on thee! Manipulation of the host immune system by myxoma virus and implications for viral-host co-adaptation. Virus Res. 88, 17-33 (2002).
14. Best, S. M. & Kerr, P. J. Coevolution of host and virus: The pathogenesis of virulent and attenuated strains of myxoma virus in resistant and susceptible European rabbits. Virology 267, 36-48 (2000).
15. Knell, R. J. Syphilis in renaissance Europe: Rapid evolution of an introduced sexually transmitted disease? Proc. Biol. Sci. 271, S174-S176 (2004).
16. Jin, M. J. et al. Mosaic genome structure of simian immunodeficiency virus from west African green monkeys. EMBO J. 13, 2935-2947 (1994).
17. Apetrei, C., Robertson, D. L. & Marx, P. A. The history of SIVS and AIDS: Epidemiology, phylogeny and biology of isolates from naturally SIV infected non-human primates (NHP) in Africa. Front. Biosci. 9, 225-254 (2004).
18. Courgnaud, V. et al. Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different cercopithecus monkeys (C. mona, C. cephus, and C. nictitans) from Cameroon. J. Virol. 77, 12523-12534 (2003).
19. Hassel, M. P. The Spatial and Temporal Dynamics of Host-Parasitoid Interactions (Oxford University Press, Oxford, 2000).
20. Diekmann, O. & Hessterbeek, O. Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis, and Interpretation (Wiley, Chichester, 2006).
21. Dronamraju, K. R. Infectious Diseases and Host-Pathogen Evolution (Cambridge University Press, Cambridge, 2004).
22. Anderson, R. M. & May, R. M. Infectious Diseases of Humans: Dynamics and Control (Oxford University Press, Oxford, 1991).
23. Arts, E. J. & Ouinones-Mateu, M. E. Sorting out the complexities of HIV-1 fitness. AIDS 17, 780-781 (2003).
24. Quinones-Mateu, M. E. & Arts, E. J. HIV-1 Fitness: Implications for Drug Resistance, Disease Progression, and Global Epidemic Evolution. [online], http://hiv.lanl.gov/content/hiv-db/COMPENDIUM/2001/partI/ Quinones.pdf (HIV Sequence Compendium, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Lcs Alamos, 2001).
25. Feng, J. Y. & Anderson, K. S. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 38, 9440-9448 (1999).
26. Deval, J. et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279, 509-516 (2004).
27. Bull, J. J. Virulence. Evolution 48, 1423-1437 (1994).
28. Bremermann, H. J. & Pickering, J. A game-theoretical model of parasite virulence. J. Theor. Biol. 100, 411-426 (1983).
29. Troyer, R. M. et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J. Virol. 79, 9006-9018 (2005).
30. Quinones-Mateu, M. E. et al. dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J. Virol. 74, 9222-9233 (2000).
31. Blaak, H., Brouwer, M., Ran, L. J., de Wolf, F. & Schuitemaker, H. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J. Infect. Dis. 177, 600-610 (1998).
32. + T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J. Infect. Dis. 190, 251-256 (2004).
33. Ewald, P. W. Evolution of Intectious Disease (Oxford University Press, Oxford, 1994).
34. Nowak, M. A. & May, R. M. Virus Dynamics: Mathematical Principles of Immunology and Virology (Oxford University Press, Oxford, 2000).
35. Maynard, S. J. Group selection and kin selection. Nature 201, 1145-1147 (1964).
36. Szathmary, E. & Maynard, S. J. From replicators to reproducers: The first major transitions leading to life. J. Theor. Biol. 187, 555-571 (1997).
37. Keele, B. F. et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313, 523-526 (2006).
38. Gao, F. et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436-441 (1999).
39. Santiago, M. L. et al. SIVcpz in wild chimpanzees. Science 295, 465 (2002).
40. Van Heuverswyn, F. et al. Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 444, 164 (2006).
41. Horimoto, T. & Kawaoka, Y. Influenza: Lessons from past pandemics, warnings from current incidents. Nature Rev. Microbiol. 3, 591-600 (2005).
42. Hirsch, V. M., Olmsted, R. A., Murphey-Corb, M., Purcell, R. H. & Johnson, P. R. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 339, 389-392 (1989).
43. Lemey, P. et al. Tracing the origin and history of the HIV-2 epidemic. Proc. Natl Acad. Sci. USA 100, 6588-6592 (2003).
44. Schim van der Loeff, M. F. & Aaby, P. Towards a better understanding of the epidemiology of HIV-2. AIDS 13, S69-S84 (1999).
45. Schim van der Loeff, M. F. et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int. J. Epidemiol. 35, 1322-1328 (2006).
46. Ayouba, A. et al. HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg. Infect. Dis. 7, 466-467 (2001).
47. Yamaguchi, J. et al. HIV-1 infections in northwestern Cameroon: identification of HIV type 1 group O and dual HIV type 1 group M and group O infections. AIDS Res. Hum. Retroviruses 20, 944-957 (2004).
48. Yamaguchi, J. et al. HIV-1 Group N: Evidence of ongoing transmission in Cameroon. AIDS Res. Hum. Retroviruses 22, 453-457 (2006).
49. Yamaguchi, J. et al. Identification of HIV type 1 group N infections in a husband and wife in Cameroon: Viral genome sequences provide evidence for horizontal transmission. AIDS Res. Hum. Retroviruses 22, 83-92 (2006).
50. Salemi, M. et al. Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution. FASEB J. 15, 276-278 (2001).
51. Travers, S. A. et al. Timing and reconstruction of the most recent common ancestor of the subtype C clade of human immunodeficiency virus type 1. J. Virol. 78, 10501-10506 (2004).
52. Arien, K. K. et al. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J. Virol. 79, 8979-8990 (2005).
53. Ball, S. C. et al. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77, 1021-1038 (2003).
54. Barnett, S. W., Quiroga, M., Werner, A., Dina, D. & Levy, J. A. Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain. J. Virol. 67, 1006-1014 (1993).
55. Talbott, R., Kraus, G., Looney, D. & Wong-Staal, F. Mapping the determinants of human immunodeficiency virus 2 for infectivity, replication efficiency, and cytopathicity. Proc. Natl Acad. Sci. USA 90, 4226-4230 (1993).
56. Pollakis, G. et al. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J. Virol. 78, 2841-2852 (2004).
57. Curran, J. W. et al. Epidemiology of HIV infection and AIDS in the United States. Science 239, 610-616 (1988).
58. Parazzini, F. et al. Number of sexual partners, condom use and risk of human immunodeficiency virus infection. Int. J. Epidemiol. 24, 1197-1203 (1995).
59. Ryder, R. W. & Behets, F. Reasons for the wide variation in reported rates of mother-to-child transmission of HIV-1. AIDS 8, 1495-1497 (1994).
60. Gray, R. H. et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357, 1149-1153 (2001).
61. Quinn, T. C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J Med. 342, 921-929 (2000).
62. Garcia, P. M. et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N. Engl. J Med. 341, 394-402 (1999).
63. Shankarappa, R. et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73, 10489-10502 (1999).
64. Zhu, T. et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261, 1179-1181 (1993).
65. Shattock, R. J. & Moore, J. P. Inhibiting sexual transmission of HIV-1 infection. Nature Rev. Microbiol. 1, 25-34 (2003).
66. Shattock, R. J., Griffin, G. E. & Gorodeski, G. I. In vitro models of mucosal HIV transmission. Nature Med. 6, 607-608 (2000).
67. Bergstrom, C. T., McElhany, P. & Real, L. A. Transmission bottlenecks as determinants of virulence in rapidly evolving pathogens. Proc. Natl Acad. Sci. USA 96, 5095-5100 (1999).
68. Lazaro, E., Escarmis, C., Perez-Mercader, J., Manrubia, S. C. & Domingo, E. Resistance of virus to extinction on bottleneck passages: Study of a decaying and fluctuating pattern of fitness loss. Proc. Natl Acad. Sci. US4 100, 10830-10835 (2003).
69. Elena, S. F. et al. Evolution of fitness in experimental populations of vesicular stomatitis virus. Genetics 142, 673-679 (1996).
70. Sagar, M. et al. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J. Virol. 77, 12921-12926 (2003).
71. Pontesilli, O. et al. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: A predominant gag-specific response is associated with nonprogressive infection. J. Infect. Dis. 178, 1008-1018 (1998).
72. Dyer, W. B. et al. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney blood bank cohort patients infected with nef-defective HIV type 1. J. Virol. 73, 436-443 (1999).
73. Cao, Y., Qin, L., Zhang, L., Safrit, J. & Ho, D. D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Eng. J. Med. 332, 201-208 (1995).
74. Pantaleo, G. et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Eng. J. Med. 332, 209-216 (1995).
75. Montefiori, D. C. et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173, 60-67 (1996).
76. + T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12, 1591-1600 (1998).
77. + T cell responses associated with control of viremia. Science 278, 1447-1450 (1997).
78. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856-1862 (1996).
79. Berger, E. A., Murphy, P. M. & Farber, J. M. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
80. Gonzalez, E. et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic. Proc. Natl Acad. Sci. USA 98, 5199-5204 (2001).
81. Gonzalez, E. et al. The influence of CCL3L 1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307, 1434-1440 (2005).
82. McDermott, D. H. et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 352, 866-870 (1998).
83. Mellors, J. W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170 (1996).
84. Collier, A. C. et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N. Engl. J. Med. 334, 1011-1017 (1996).
85. Silvestri, G. et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity. 18, 441-452 (2003).
86. Rodriguez, B. et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296, 1498-1506 (2006).
87. Deacon, N. J. et al. Genomic structure of an attenuated quasispecies of HIV-1 from a blood transfusion donor and recipients. Science 270, 988-991 (1995).
88. Kirchhoff, F., Greenough, T. C., Brettler, D. B., Sullivan, J. L. & Desrosiers, R. C. Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Eng. J. Med. 332, 228-232 (1995).
89. Huang, Y., Zhang, I. & Ho, D. D. Biological characterization of nef in long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 69, 8142-8146 (1995).
90. Leroux, C., Issel, C. J. & Montelaro, R. C. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J. Virol. 71, 9627-9639 (1997).
91. Plagemann, P. G., Chen, Z. & Li, K. Replication competition between lactate dehydrogenase-elevating virus quasispecies in mice. Implications for quasispecies selection and evolution. Arch. Virol. 146, 1283-1296 (2001).
92. Lu, J. & Kuritzkes, D. R. A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants. J. Acquir. Immune. Defic. Syndr. 27, 7-13 (2001).
93. Holland, J. J., de la Torre, J. C., Clarke, D. K. & Duarte, E. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J. Virol. 65, 2960-2967 (1991).
94. Domingo, E., Escarmis, C., Menendez-Arias, L. & Holland, J. in Origin And Evolution of Viruses (eds Domingo, E., Webster, R. & Holland, J.) 141-161 (Academic Press, San Diego, 1999).
95. Harrigan, P. R., Bloor, S. & Larder, B. A. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 72, 3773-3778 (1998).
96. Ouinones-Mateu, M. E. & Arts, E. J. Virus fitness: Concept, quantification, and application to HIV population dynamics. Curr. Top. Microbiol. Immunol. 299, 83-140 (2006).
97. Clarke, D. K. et al. The red queen reigns in the kingdom of RNA viruses. Proc. Natl Acad. Sci. USA 91, 4821-4824 (1994).
98. Novella, I. S. et al. Exponential increases of RNA virus fitness during large population transmissions. Proc. Natl Acad. Sci. USA 92, 5841-5844 (1995).
99. Chao, L. Fitness of RNA virus decreased by Muller's ratchet. Nature 348, 454-455 (1990).
100. Domingo, E. & Holland, J. J. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51, 151-178 (1997).
101. Yuste, E., Sanchez-Palomino, S., Casado, C., Domingo, E. & Lopez-Galindez, C. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J. Virol. 73, 2745-2751 (1999).
102. Mullins, J. I. & Jensen, M. A. Evolutionary dynamics of HIV-1 and the control of AIDS. Curr. Top. Microbiol. Immunol. 299, 171-192 (2006).
103. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
104. + T-cell responses: Relationship to viral load in untreated HIV infection. J. Virol. 75, 11983-11991 (2001).
105. Rosenberg, E. S. et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523-526 (2000).
106. Goulder, P. J. et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193, 181-194 (2001).
107. Goulder, P. J. & Watkins, D. I. HIV and SIV CTL escape: Implications for vaccine design. Nature Rev. Immunol. 4, 630-640 (2004).
108. Cao, K. et al. Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens 63, 293-325 (2004).
109. Moore, C. B. et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296, 1439-1443 (2002).
110. Goulder, P. J. et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412, 334-338 (2001).
111. Leslie, A. J. et al. HIV evolution: CTL escape mutation and reversion after transmission. Nature Med. 10. 282-289 (2004).
112. Martinez-Picado, J. et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80, 3617-3623 (2006).
113. Troyer, R. M. et al. The fitness cost of CTL escape: Not a terrible hardship on HIV-1? [online], http://www.iasociety.org/abstract/ show.asp?abstract_id=2199593 (XVI International AIDS Conference, Toronto, Canada 13-18 August, 2006)
114. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
115. Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853 (2004).
116. Markowitz, M. et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: A case report. Lancet 365, 1031-1038 (2005).
117. Van de, P. P. Viral and host determinants of HIV-1 pathogenesis, AIDS 20, 933-934 (2006).
118. Muller, V. & De Boer, R. J. The integration hypothesis: An evolutionary pathway to benign SIV infection. PLoS Pathog. 2, e15 (2006).
119. Muller, V. et al. Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS 20, 889-894 (2006).
120. Kannangara, S., DeSimone, J. A. & Pomerantz, R. J. Attenuation of HIV-1 infection by other microbial agents. J. Infect. Dis. 192, 1003-1009 (2005).
121. Arien, K. K. et al. Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. AIDS 19, 1555-1564 (2005).
122. Yerly S. et al. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354, 729-733 (1999).
123. Turner, D. & Wainberg, M. A. HIV transmission and primary drug resistance. AIDS Rev. 8, 17-23 (2006).
124. Eyster, M. E. Test may predict which patients with HIV infection will develop AIDS. Am. Fam. Physician 39, 276 (1989).
125. + T-cell depletion in HIV disease. Nature 410, 974-979 (2001).
126. Marlink, R. et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265, 1587-1590 (1994).
127. Matheron, S. et al. Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort. AIDS 17, 2593-2601 (2003).
128. Gilbert, P. B. et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat. Med. 22, 573-593 (2003).
129. Kanki, P. J. et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343, 943-946 (1994).
130. Essex, M. Human immunodeficiency viruses in the developing world. Adv. Virus Res. 53, 71-88 (1999).
131. Luo, C. C. et al. HIV-1 subtype C in China. Lancet 345, 1051-1052 (1995).
132. Piyasirisilp, S. et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J. Virol. 74, 11286-11295 (2000).
133. Soares, E. A. et al. HIV-1 subtype C dissemination in southern Brazil. AIDS 19, S81-S86 (2005).
134. Vidal, N. et al. Distribution of HIV-1 variants in the Democratic Republic of Congo suggests increase of subtype C in Kinshasa between 1997 and 2002. J. Acquir. Immune. Defic. Syndr. 40, 456-462 (2005).
135. Walker, P. R., Pybus, O. G., Rambaut, A. & Holmes, E. C. Comparative population dynamics of HIV-1 subtypes B and C: Subtype-specific differences in patterns of epidemic growth. Infect. Genet. Evol. 5, 199-208 (2005).
136. Renjifo, B. et al. Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. J. Hum. Virol. 4, 16-25 (2001).
137. Renjifo, B. et al. Preferential in utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS 18, 1629-1636 (2004).
138. Yang, C. et al. Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission. AIDS 17, 1667-1674 (2003).
139. Eshleman, S. H. et al. Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis. HIV Network For Prevention Trials 012. J. Acquir. Immune. Defic. Syndr. 39, 593-597 (2005).
140. Pope, M. et al. Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism. J. Virol. 71, 8001-8007 (1997).
141. Dittmar, M. T. et al. Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups. J. Virol. 71, 8008-8013 (1997).
142. Tovanabutra, S. et al. The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. AIDS Res. Hum. Retroviruses. 20, 465-475 (2004).
143. Zaitseva, M. et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection. Nature Med. 3, 1369-1375 (1997).
144. Arien, K. K. et al. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J. Virol. 79, 8979-8990 (2005).
145. Johnston, E. R. et al. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J. Virol. 77, 7682-7688 (2003).
146. Gupta, S., Anderson, R. M. & May, R. M. Networks of sexual contacts: implications for the pattern of spread of HIV. AIDS 3, 807-817 (1989).
147. Anderson, R. M., Ng, T. W., Boily, M. C. & May, R. M. The influence of different sexual-contact patterns between age classes on the predicted demographic impact of AIDS in developing countries. Ann. N. Y. Acad. Sci. 569, 240-274 (1989).
148. Pilcher, C. D., Eron, J. J. Jr, Galvin, S., Gay, C. & Cohen, M. S. Acute HIV revisited: New opportunities for treatment and prevention. J. Clin. Invest. 113, 937-945 (2004).
149. Jacquez, J. A., Koopman, J. S., Simon, C. P. & Longini, I. M. Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J. Acquir. Immune. Defic. Syndr. 7, 1169-1184 (1994).
150. Koopman, J. S. et al. The role of early HIV infection in the spread of HIV through populations. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 14, 249-258 (1997).
151. Ndung'u, T. et al. Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model. J. Virol. 75, 11417-11425 (2001).
152. + T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res. Hum. Retroviruses 21, 285-291 (2005).
153. Neilson, J. R. et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J. Virol. 73, 4393-4403 (1999).
154. Kaleebu, P. et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J. Infect. Dis. 185, 1244-1250 (2002).
155. Vasan, A. et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin. Infect. Dis. 42, 843-852 (2006).
156. Kaleebu, P. et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 15, 293-299 (2001).
157. Choge, I. et al. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res. Hum. Retroviruses 22, 458-465 (2006).
158. Senkaali, D. et al. The relationship between HIV type 1 disease progression and V3 serotype in a rural Ugandan cohort. AIDS Res. Hum. Retroviruses 20, 932-937 (2004).
159. Arts, E. J. et al. Infection with subtype C HIV-1 of lower replicative fitness as compared to subtypes A and D leads to slower disease progression in Zimbabwean and Ugandan women. [online], http://www.iasociety.org/abstract/show.asp?abstract_id=2199440 (XVI International AIDS Conference, Toronto, Canada 13-18 August, 2006).
160. Pierson, T., McArthur, J. & Siliciano, R. F. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol. 18, 665-708 (2000).
161. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
162. Li, D. Q., Zheng, X. W. & Zhang, G. Y. Study on the distribution HIV-1 C subtype in Ruili and other counties, Yunnan, China (Translation). Zhonghua Liu Xing. Bing. Xue. Za Zhi. 17, 337-339 (1996).
163. Li, X. J. et al. Molecular epidemiology of the heterosexual HIV-1 transmission in Kunming, Yunnan Province of China suggests origin from the local IDU epidemic. AIDS Res. Hum. Retroviruses 21, 977-980 (2005).
164. Van Harmelen, J. H. et al. A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. AIDS Res. Hum. Retroviruses 15, 395-398 (1999).
165. Rainwater, S. et al. No evidence for rapid subtype c spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res. Hum. Retroviruses 21, 1060-1065 (2005).